Cabotegravir Injectable Suspension (CAB LA)

DRUG2 trials

Sponsors

ViiV Healthcare, Johns Hopkins University

Conditions

HIVHIV InfectionsInjectableProphylaxis

Phase 1

Cabotegravir-Hormone PK/PD Interactions for HIV Prevention

RecruitingNCT07672717

Johns Hopkins UniversityHIV, Injectable, Prophylaxis

Start: 2026-07-07End: 2031-12-01Target: 32Updated: 2026-07-13

Phase 3

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

CompletedNCT04542070

ViiV HealthcareHIV Infections

Start: 2020-11-09End: 2023-04-17Updated: 2024-06-04

Related Papers

Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study.

2025-10-17

Efficacy and safety of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in Japanese participants: 12-month results from the phase 3b randomized SOLAR trial.

2025-05-16

Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.

2024-10-086 citations

1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF

Open Forum Infectious Diseases2023-11-273 citations

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.

2023-08-0871 citations

875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants

Open Forum Infectious Diseases2021-11-01

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

2021-05-3156 citations